Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.
IPO Year:
Exchange: NASDAQ
Website: mereobiopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/13/2024 | $8.00 | Outperform | Robert W. Baird |
| 10/13/2023 | $4.00 | Buy | BTIG Research |
| 8/12/2022 | $4.00 | Overweight | Cantor Fitzgerald |
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT. A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company's website for two weeks following the live event. About Mereo BioPharma Mereo BioPharma
Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $80.5 million as of September 30, 2024, which the Company believes will provide runway into 2027, through multiple key inflection points. "The Phase 3 program for setrusumab
LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:55am ET / 03:55pm BST. A live audio webcast can be accessed through the Investors section of the Company's website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company's website for two weeks following the live event. About Mereo BioPharmaMereo BioPharma is a biopharma
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $87.4 million as of June 30, 2024,
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares ("ADSs"). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. Each ADS represents five ordinary shares of Mereo. The net proceeds of this offering are expected to b
14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment resulted in continued, substantial improvements in bone mineral density (BMD) with a mean increase from baseline of 22% (p<0.0001) and a mean improvement in Z-score of +1.25 (p<0.0001) NOVATO, Calif. and LONDON, June 11, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO) today announced positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study (NCT05125809) demonstrating that, as of a May 24, 2024 data cut
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST. A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company's website for two weeks following the live event. About Mereo BioPharma Mereo BioPharma is a
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026. "2024 is off to an exciting start following the completion of enrollment by our partner Ultragenyx in both the Orbit and Cosmic studies of setrusumab in Osteogenesis Imperfecta (OI) along with the continued advancement of the pre-laun
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST. A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company's website for two weeks following the live event. About Mereo BioPharma Mereo
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partner around the end of 2024 Cash of $57.4 million as of December 31, 2023 expected to fund operations into 2026 LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2023, and provided an update on recent co
144 - Mereo BioPharma Group plc (0001719714) (Subject)
144 - Mereo BioPharma Group plc (0001719714) (Subject)
144 - Mereo BioPharma Group plc (0001719714) (Subject)
144 - Mereo BioPharma Group plc (0001719714) (Subject)
10-Q - Mereo BioPharma Group plc (0001719714) (Filer)
8-K - Mereo BioPharma Group plc (0001719714) (Filer)
144/A - Mereo BioPharma Group plc (0001719714) (Subject)
144/A - Mereo BioPharma Group plc (0001719714) (Subject)
144/A - Mereo BioPharma Group plc (0001719714) (Subject)
144 - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13D/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13D/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
Robert W. Baird initiated coverage of Mereo BioPharma with a rating of Outperform and set a new price target of $8.00
BTIG Research resumed coverage of Mereo BioPharma with a rating of Buy and set a new price target of $4.00
Cantor Fitzgerald initiated coverage of Mereo BioPharma with a rating of Overweight and set a new price target of $4.00
BTIG Research initiated coverage of Mereo BioPharma with a rating of Buy and set a new price target of $10.00
Needham initiated coverage of Mereo BioPharma with a rating of Buy and set a new price target of $10.00
LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company's Board of Directors, effective immediately. Dr. Mullick joins Mereo's Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geographies, including in rare diseases. "We are very excited to welcome Abdul to the Board at such a pivotal time for the Company," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "His e
LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company's Board of Directors, effective immediately. Ms. Hyland has also been appointed to serve on the Audit and Risk Committee of the Board. Ms. Hyland joins Mereo's Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space. "We are very excited to welcome someone with Anne's level of operational and board experience to our Board," said Dr. Denise Scots-Knight, C
LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company's Board of Directors, effective September 20, 2021. Dr. Jacquet joins Mereo's Board with over two decades of multidisciplinary experience in the life science industry, including corporate strategy, M&A advisory and value management. "We are delighted to have Pierre joining our board of directors at such an exciting and important time for the Company," said Dr. Denise Scots-Knight, Chief Executive Off
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026. "2024 is off to an exciting start following the completion of enrollment by our partner Ultragenyx in both the Orbit and Cosmic studies of setrusumab in Osteogenesis Imperfecta (OI) along with the continued advancement of the pre-laun
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partner around the end of 2024 Cash of $57.4 million as of December 31, 2023 expected to fund operations into 2026 LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2023, and provided an update on recent co
Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to screen patients Conference call to discuss data planned for 5 p.m. Eastern Time NOVATO, Calif. and LONDON, June 05, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO) today announced data from the dose-selection Phase 2 portion of the Phase 2/3 Orbit study showing that setrusumab rapidly induced bone production in OI-affected patients. Across all patients evaluated setrusumab demonstrated statistically significant increases in
LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights. "In 2022, we made important progress in the ongoing advancement of our core rare disease programs. The data from our Phase 2 ASTRAEUS study of alvelestat in severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) were highly encouraging, and formed the basis for productive discussions with the regulatory agencies in both the U.S. and EU, culminating in our recent annou
Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU No additional confirmatory study required Company to host conference call today at 8:30am ET LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases, today announced regulatory feedback following recent end-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) related to its alvelestat program for the treatment of alpha-1-antitrypsin d
Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period Statistically significant reductions in the biomarkers Aα-val360 and desmosine at the high dose demonstrating clear impact of alvelestat on the pathogenic pathway of AATD-lung disease No safety signals were associated with alvelestat Conference Call Today at 10:30 a.m. ET LONDON and REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), ("Mereo" or "the Company"), a clinical-stage biopharmaceutical company focused on oncology and rare d
LONDON and REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its "ASTRAEUS" Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema. Conference Call Details:US: (866) 374-5140(International): (404) 400-0571Conference ID: 50222760 A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.mereobiopharma.com. The archived webcast will re
One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set Etigilimab was well tolerated with a favorable safety profile Conference call today at 8:30am ET LONDON and REDWOOD CITY, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today reported promising interim efficacy, safety, and biomarker data on patients from ACTIVATE, a Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with nivolumab in select recurrent advanced / metastatic solid tumors. "Thes
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 price target.
Leerink Partners analyst Joseph Schwartz maintains Mereo BioPharma Group (NASDAQ:MREO) with a Outperform and raises the price target from $6 to $8.
Baird analyst Jack Allen initiates coverage on Mereo BioPharma Group (NASDAQ:MREO) with a Outperform rating and announces Price Target of $8.
Shares of Streamline Health Solutions, Inc. (NASDAQ:STRM) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results. Streamline Health reported quarterly losses of 5 cents per share which missed the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $4.33 million which beat the analyst consensus estimate of $4.31 million, according to data from Benzinga Pro. Streamline Health Solutions shares dipped 23.3% to $0.4902 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers DDC Enterprise Limited (NYSE:DDC) surged 101% to $1.04. DDC Enterprise said it has acqu
Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 price target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised the price target for Oracle Corporation (NYSE:ORCL) from $140 to $150. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Oracle shares fell 0.5% to close at $123.88 on Tuesday. See how other analysts view this stock. Telsey Advisory Group cut the price target for Academy Sports and Outdoors, Inc. (NASDAQ:ASO) from $75 to $65. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating. Academy Sports shares fell 3.2% to close at $51.69 on Tu
Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and raises the price target from $6 to $7.
Shares of Oracle Corporation (NYSE:ORCL) rose sharply in today's pre-market trading after the company reported fourth-quarter financial results. Oracle posted weaker-than-expected earnings for its fiscal fourth quarter. The company also announced a partnership with Alphabet Inc’s (NASDAQ:GOOGL) (NASDAQ:GOOG) Google Cloud. Oracle shares jumped 9% to $135.00 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Golden Heaven Group Holdings Ltd (NASDAQ:GDHG) rose 70.3% to $0.3049 in today's pre-market trading. WANG & LEE GROUP, Inc. (NASDAQ:WLGS) shares rose 43.1% to $0.8760 in pre-market trading after surging 16% on Tuesday. S